title: Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.
abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma (NHL). DLBCL is clinically, pathologically and molecularly heterogeneous disease. Various clinical, pathological and molecular markers have been developed to characterize the disease. Based on these characterizations, new targeted agents are being investigated to optimize the treatment and improve the outcomes of DLBCL. Enhanced molecular understanding, invention of targeted agents and immunotherapy has opened the doors for improvement in the treatment of DLBCL. In this review, we will discuss various prognostic markers of DLBCL and their potential therapeutic implications.
authors.affiliation: a Hematology & Oncology, Department of Medicine , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Muhammad O
authors.initials: MO
authors.lastname: Jamil
authors.affiliation: a Hematology & Oncology, Department of Medicine , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Amitkumar
authors.initials: A
authors.lastname: Mehta
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers; D020869:Gene Expression Profiling; D014644:Genetic Variation; D006801:Humans; D007150:Immunohistochemistry; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000209:etiology / Q000401:mortality* / Q000628:therapy; D058990:Molecular Targeted Therapy; D049268:Positron-Emission Tomography; D011379:Prognosis; D015398:Signal Transduction / Q000187:drug effects; D059016:Tumor Microenvironment
chemical_list: D015415:Biomarkers
keywords: Diffuse large B cell lymphoma; Prognostic marker; bortezomib; brentuximab vedotin; ibrutinib; lenalidomide